Company Overview of Immune Design Corp.
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo immunotherapy treatments. It develops various product candidates based on its ZVex and GLAAS product discovery platforms. The company’s products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 that is in Phase 1 trial for the treatment of patients with relapsed or metastatic melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1; and G100, an intratumoral immune activation product candidate for the treatment of patients with Merkel cell carcinoma and non-Hodgkin Lymphoma. In addition, its technologies are ...
1616 Eastlake Avenue East
Seattle, WA 98102
Founded in 2008
Key Executives for Immune Design Corp.
Chief Executive Officer, President and Director
Total Annual Compensation: $530.5K
Principal Financial Officer, Principal Accounting Officer and Executive Vice President of Strategy & Finance
Total Annual Compensation: $331.0K
Compensation as of Fiscal Year 2015.
Immune Design Corp. Key Developments
Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate
Feb 22 17
Immune Design announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational intratumoral therapy, G100, for the treatment of follicular non-Hodgkin’s lymphoma. Orphan Drug Designation is granted by the FDA Office of Orphan Drug Products to products that treat rare diseases. The FDA defines rare diseases as those affecting fewer than 200,000 people in the United States. Orphan Drug Designation provides the sponsor certain benefits and incentives, including a period of marketing exclusivity for the first marketing application, if regulatory approval is received for the designated indication, potential tax credits for certain activities and waiver of certain administrative fees. G100 is a product candidate from Immune Design's GLAAS® discovery platform. It contains a potent synthetic
small molecule toll-like receptor-4 (TLR-4) agonist, Glucopyranosyl Lipid A (GLA), and is the lead product candidate in Immune Design’s Antigen Agnostic approach. It leverages the activation of both innate and adaptive immunity, including Dendritic Cells, in the tumor microenvironment to create an immune response against the tumor's preexisting diverse set of antigens. A growing set of clinical and preclinical data have demonstrated the ability of G100 to activate tumor-infiltrating lymphocytes, macrophages and dendritic cells, and promote antigen-presentation and the recruitment of T cells to the tumor.
Immune Design Corp. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-16-2017 10:30 AM
Jan 24 17
Immune Design Corp. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-16-2017 10:30 AM. Venue: Lotte New York Palace, 455 Madison Ave., New York, New York, United States. Speakers: Carlos V. Paya, Chief Executive Officer, President and Director.
Richard Kenney Resigns as Principal Medical Advisor of Immune Design Corp
Dec 16 16
On December 16, 2016, Richard Kenney, M.D. resigned as Principal Medical Advisor of Immune Design Corp.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|